Jay J. Gambale

Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects

Kenneth C. Lasseter, Jay J. Gambale, Bo Jin et al. · The Journal of Clinical Pharmacology · 2007 · 133 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Effects of JNJ‐38431055, a novel GPR119 receptor agonist, in randomized, double‐blind, placebo‐controlled studies in subjects with type 2 diabetes

Leonid Katz, Jay J. Gambale, Paul Rothenberg et al. · Diabetes Obesity and Metabolism · 2012 · 108 citations

Medicine, Pharmacokinetics, Pharmacology +12

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of JNJ-38431055, a Novel GPR119 Receptor Agonist and Potential Antidiabetes Agent, in Healthy Male Subjects

Leonid Katz, Jay J. Gambale, Paul Rothenberg et al. · Clinical Pharmacology & Therapeutics · 2011 · 48 citations

Medicine, Pharmacokinetics, Pharmacology +16

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

Walter J. Loos, Ronald de Wit, Steven J. Freedman et al. · Cancer Chemotherapy and Pharmacology · 2006 · 48 citations

Medicine, Pharmacokinetics, Pharmacology +6

Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects

Elizabeth Migoya, Arthur Bergman, David Hreniuk et al. · International Journal of Clinical Pharmacology and Therapeutics · 2006 · 21 citations

Pharmacy, Pharmacology, Pharmacotherapy +17